According to the first annual resport into clinical trials by the Association of the British Pharmaceutical Industry, the United Kingdom is leading the rest of Europe in early-stage clinical research into new medicines and vaccines.
According to the first annual resport into clinical trials by the Association of the British Pharmaceutical Industry (ABPI), the United Kingdom is leading the rest of Europe in early-stage clinical research into new medicines and vaccines.
Some areas of strength for the UK’s clinical research sector include cancer, heart disease, immunology, and conditions affecting the nervous system. However, the report also highlights that despite the UK’s leading position at early stages of clinical research, it drops below Germany and Spain when the research progresses to later stages. On the global stage, the UK falls to fifth, with the United States and Canada joining Germany and Spain in the top four positions.
Additionally, ABPI revealed in a Nov. 21, 2019 press release, that the UK is also set to encounter a number of challenges, such as Brexit and increasing competition, that will impact the country’s rankings at both the European and global level. As the US continues to dominate the sector and with Asia rapidly growing, ABPI reports that maintaining a strong sector in the UK will be integral to supporting continued investment in European science collaborations.
In the report, ABPI provides seven recommendations to help ensure the UK not only maintains but also grows its position as a medicines R&D hub. These recommendations include increasing investment, building a suitable workforce, simplifying the clinical trials processes, and ensuring a future UK-Europe relationship for medicines research during the period of Brexit uncertainty.
“The report shows the importance of the UK globally and the pressing need to keep pace with other established and emerging research hubs in order to continue to attract commercial clinical research,” said Dr Sheuli Porkess, executive director of research, medical, and innovation at the ABPI, in the press release.
“The UK’s world-leading clinical research sector is a rare good news story, and the next government cannot let this position slip,” added Professor Andrew Goddard, president of the Royal College of Physicians. “Amid the heat of Brexit, we must continue to invest in life-sciences research.”
More information and details on the report can be found on ABPI’s website.
Source: ABPI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.